Sarepta Reports Q1 2026 Earnings: ELEVIDYS Stabilization and Pipeline Advances
Event summary
- Sarepta reported Q1 2026 revenues of $730.8M, down 2% YoY, primarily due to lower ELEVIDYS sales following label updates.
- Earned $40M milestone payment from Roche for first commercial sale of ELEVIDYS in Japan.
- Submitted sNDAs to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals.
- Enrolled and dosed first patients in ENDEAVOR Cohort 8 study for non-ambulatory Duchenne patients.
- Shared early clinical data for siRNA pipeline targeting FSHD1 and DM1, showing favorable tolerability.
The big picture
Sarepta is navigating a strategic inflection point, balancing commercial stabilization of its Duchenne portfolio with pipeline advancements in genetic medicine. The company's ability to execute across these fronts will determine its leadership position in rare disease therapeutics. With positive cash flow and a robust pipeline, Sarepta aims to define its next era of growth through precision genetic medicine.
What we're watching
- Commercial Recovery
- Whether Sarepta can restore ELEVIDYS growth through expanded field engagement and disease-modifying evidence.
- Pipeline Progress
- The pace of clinical readouts across Sarepta's siRNA portfolio, particularly for FSHD1 and DM1 programs.
- Regulatory Momentum
- How the sNDA submissions for AMONDYS 45 and VYONDYS 53 will impact their market positioning.
Related topics